AHA 2018 VITAL evaluated both vitamin D and omega-3 supplementation and did not find effect on the primary cancer and CV endpoints. Secondary endpoints suggest lower total MI with omega-3 suplementation.
AHA 2018 Adm. Giroir emphasizes the importance for anyone of being physically active, and how recommended levels can easily be achieved. This is important for individual health, but also for national security.
AHA 2018 Deepak Bhatt considers the compounds that were tested in the VITAL and REDUCE-IT trials, which yielded neutral and very positive results, respectively, and what likely caused this discrepancy.
AHA 2018 U.S. Department of Health & Human Services and AHA teamed up to engage entire communities to be more physically active, by highlighting the evidence that shows that health will benefit from it.
AHA 2018 Dapagliflozin was evaluated in both primary and secondary prevention patients with T2DM. Stephen Wiviott summarizes the results of DECLARE TIMI-58, along with those of a meta-analysis of the 3 SGLT2i CVOTs.
AHA 2018 Paul Ridker outlines how the new CIRT results add to our understanding of inflammation biology in relation to CV risk and how this directs future studies of inflammation.
AHA 2018 Dorairaj Prabhakaran showed improved quality of life and return to pre-infarct daily activities with the Yoga-CaRe program as replacement for cardiac rehabilitation in post-MI patients.
AHA 2018 Dapagliflozin was associated with a reduction in CVD/hospitalization in T2DM patients with ASCVD or with multiple risk factors, and with a modest decrease in MACE in those with existing ASCVD.
AHA 2018 Low-dose methotrexate did not lower IL-1β, IL-6 and CRP levels, nor did it reduce atherosclerotic events in patients with stable CAD, suggesting that the IL-1β to IL-6 to CRP pathway is important for atheroprotection.
AHA 2018 Icosapent ethyl resulted in a 25% risk reduction of important ischemic events and also reduced CV death in well-treated patients with elevated triglyceride levels at risk of CV events in the REDUCE-IT trial.
AHA 2018 Neil Stone served as vice-president of the new cholesterol guideline. He sums up the main new recommendations based on the latest evidence of recent lipid outcome trials.
AHA 2018 The American Heart Association (AHA) and the American College of Cardiology (ACC) updated the 2018 cholesterol guidelines. A summary of key recommendations concerning cholesterol management in de prevention of CVD.